Aldeyra Therapeutics Inc ALDX:NASDAQ

Last Price$3.25NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.22 (1)
Ask (Size)$3.33 (2)
Day Low / HighN/A - N/A
Volume915.2 K

View Biotechnology IndustryPeer Comparison as of 01/21/2022


Aldeyra Therapeutics Inc ( NASDAQ )

Price: $3.25
Change: -0.22 (6.34%)
Volume: 915.2 K
4:00PM ET 1/21/2022

Athersys Inc ( NASDAQ )

Price: $0.80
Change: -0.04 (4.53%)
Volume: 1.8 M
4:00PM ET 1/21/2022

Leap Therapeutics Inc ( NASDAQ )

Price: $2.11
Change: -0.28 (11.72%)
Volume: 3.5 M
4:00PM ET 1/21/2022

9 Meters Biopharma Inc ( NASDAQ )

Price: $0.75
Change: -0.04 (5.10%)
Volume: 2.5 M
4:00PM ET 1/21/2022

Homology Medicines Inc ( NASDAQ )

Price: $3.37
Change: -0.13 (3.71%)
Volume: 368.2 K
4:00PM ET 1/21/2022

Read more news Recent News

Aldeyra Says Reproxalap Demonstrates Symptom Improvement Over Xiidra in Mid-Stage Trial in Dry Eye Disease
9:51AM ET 1/11/2022 MT Newswires

Aldeyra Therapeutics (ALDX) said Tuesday that patient-reported ocular discomfort and itching were "statistically lower" with reproxalap compared with...

Aldeyra Therapeutics Completes Enrollment in Part 1 of Phase 3 Trial for Eye Disease Drug
9:59AM ET 1/04/2022 MT Newswires

Aldeyra Therapeutics (ALDX) said Tuesday it completed enrollment in the first part of the phase 3 trial of ADX-2191 in patients with proliferative...

--Berenberg Bank Adjusts Aldeyra Therapeutics PT to $28 From $32, Maintains Buy Rating
8:37AM ET 12/22/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sector Update: Health Care Stocks Edging Higher Near Tuesday Close
4:02PM ET 12/21/2021 MT Newswires

Health care stocks held small gains ahead of Tuesday's close, with the NYSE Health Care Index rising 0.4% and the Health Care Select Sector SPDR ETF (XLV)...

Company Profile

Business DescriptionAldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA. View company web site for more details
Address131 Hartwell Avenue
Lexington, Massachusetts 02421
Number of Employees19
Recent SEC Filing01/04/2022SC 13G/A
President, Chief Executive Officer & DirectorTodd C. Brady
Chief Financial OfficerJoshua Reed
Vice President & ControllerBruce Greenberg
Senior Vice President-Clinical DevelopmentJames A. Gow

Company Highlights

Price Open$3.42
Previous Close$3.47
52 Week Range$3.24 - 15.95
Market Capitalization$188.8 M
Shares Outstanding58.1 M
SectorHealth Technology
Next Earnings Announcement03/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.06
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-33.38%

Analyst Ratings as of 12/20/2021

Consensus RecommendationConsensus Icon
Powered by Factset